Drug Trials Snapshot: NEXVIAZYME
NEXVIAZYME is an enzyme used for the treatment of patients 1 year of age and older with late-onset Pompe disease…
FDA Drug Safety Communication: UPDATE on Tumor Necrosis Factor (TNF) blockers and risk for pediatric malignancy
[11-03-2011] The U.S. Food and Drug Administration (FDA) is updating the public about its ongoing safety review of Tumor Necrosis…
Spotlight on CDER Science
FDA scientists carry out laboratory, clinical and analytical research to address knowledge gaps in drug development, healthcare technologies and post-market…
CDER Communications Testing: Optimizing Drug Information Through Target Audience Feedback
Social and behavioral scientists in CDER’s Office of Communications (OCOMM) collect feedback from target audience members on a variety of…
FDA Drug Safety Communication: FDA review results in new warnings about using general anesthetics and sedation drugs in young children and pregnant women
Repeated or lengthy use of general anesthetic and sedation drugs in children younger than 3 years or in pregnant women…
FDA Drug Safety Communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS)
A U.S. Food and Drug Administration (FDA) review of four large clinical safety trials shows that treating asthma with long-acting…
5 questions about Trump’s tariff plans
Here’s what importers need to know ahead of the potential implementation of tariffs this week.
AAFA again urges reform for garment workers in Bangladesh
Representatives from the trade organization joined VF Corp. and Columbia Sportswear in Dhaka to advocate for improved labor conditions.
UPS to cut Amazon volume by more than 50%
The reduction will occur by the second half of 2026 as part of the carrier’s push to deliver more profitable…
LTL freight classification changes: Upcoming dates to know
More details on the proposed changes will be released Thursday, kicking off a public comment period.